HOUSTON, TX – May 14, 2019 — Precision for Medicine, a Precision Medicine Group company, announced that it will provide its state-of-the-art laboratory services to perform drug assessment as part of a new personalized clinical trial designed to identify the most effective therapies for individual lymphoma patients at The University of Texas MD Anderson Cancer Center.
The novel study will utilize Precision for Medicine’s Houston-based CLIA certified lab (formerly ApoCell, Inc.) to conduct real-time stratification studies on a specially selected group of B-Cell Lymphoma patients, screening up to 30 different drugs for each patient to determine the most effective treatment for that individual. Using each patient’s own tumor cells, samples will be isolated and tested for response to specific therapies, with results generated within 24-48 hours and communicated back to investigators within MD Anderson’s Lymphoma Moon Shot™, part of MD Anderson’s Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives. Using guidance derived from Precision’s lab testing, the investigators can then align each patient with the best treatment in an accelerated timeframe, thereby extending overall survival.
The Lymphoma Moon Shot™ is led by Michael Wang, M.D., professor of Lymphoma & Myeloma, who is also lead investigator on the MD Anderson-Precision for Medicine investigation.
“This work is significant in that allows us to utilize our state-of-the-art CLIA lab to process assays on a large scale, analyzing several thousand samples over a very short timeframe. By individually screening up to 30 therapies for each patient, this approach has the potential to improve patient outcomes and extend the lives of these individuals, truly delivering upon the promise of personalized medicine. We are very pleased to be a part of this important initiative,” said Dr. Darren Davis, Senior Vice President and project supervisor for Precision for Medicine.
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with more than 1,800 employees in 31 locations in the US, Canada, and Europe. For more information, visit precisionformedicine.com.
# # #
Louis Landon, Precision Medicine Group Media Relations